This website is intended for Australian healthcare professionals.

Updates in the adjuvant
treatment landscape in
high-risk MIUC after radical
resection

The treatment landscape for high-risk MIUC following radical resection has continued to evolve with adjuvant immunotherapy becoming an available option.¹

Find out more

Neoadjuvant treatment choices can impact adjuvant treatment options.

Has your MDT discussed all options?

Learn more about these changes and what this means for your practice:

See what's new

A quick summary to understand recent changes

Download

Hear from the experts

Hear from international urology and medical oncology experts as they discuss multidisciplinary collaboration in MIUC decision-making and the role of adjuvant therapy in eligible patients

Watch videos

Stay up to date

Review the latest clinical data for adjuvant immunotherapy in high-risk MIUC following radical resection

Learn more

This website is for Australian healthcare professionals only. If you are a patient or a member of the general public, please speak with your doctor.

MDT = multidisciplinary team; MIUC = muscle invasive urothelial cancer.

References: 1. Pharmaceutical Benefits Scheme (www.pbs.gov.au).

This website is intended for Australian Healthcare Professionals.

© 2024 Bristol-Myers Squibb. BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd,
ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3160. 1506-AU-2400260. August 2024. BRMSOY0225.

Updates in the adjuvant treatment landscape in high-risk MIUC after radical resection

Has your MDT discussed all options?

Updates in the adjuvant
treatment landscape in
high-risk MIUC after radical
resection